For the Inventor, By the Inventor

Enter assignee name

Sawai Pharmaceutical Co., Ltd.

USPTO Granted Patents = 28

EPO Patents = 4

Trademarks = 3

Forward Citations = 61

where 'Filed Patents' based on already Granted Patents

where 'Inventors Filed' based on already Granted Patents

56 inventors (with patents filed for the assignee):

Yoshiko Kato (10 out of 10 patents)

Junji Yoshinaga (9 out of 9 patents)

Kenji Nozawa (8 out of 9 patents)

4. Hiroaki Kikuoka (7 out of 7 patents)

5. Wataru Izui (5 out of 5 patents)

6. Hiroyuki Yamamoto (5 out of 25 patents)

7. Michinori Oikawa (4 out of 4 patents)

8. Hitoshi Matsumoto (4 out of 21 patents)

9. Takeshi Shogaki (4 out of 4 patents)

10. Takao Kakita (4 out of 4 patents)

11. Hisao Kakegawa (4 out of 15 patents)

12. Toshio Satoh (4 out of 26 patents)

13. Juichi Riku (4 out of 4 patents)

14. Yoshifumi Kanamoto (4 out of 4 patents)

15. Yasufumi Okamura (3 out of 3 patents)

28 patents: Sort by Forward Citations

1. 12458600 - Method for producing granules containing a core particle, granules containing a core particle, pharmaceutical composition containing the granules containing the core particle, and preparation containing the pharmaceutical composition (2025-11-04),

2. 12419840 - Preparation containing saxagliptin and method for producing the same (2025-09-23),

3. 12409145 - Granule, preparation containing the granule, production method of the granule, and production method of preparation containing the granule (2025-09-09),

4. 11826473 - Orally disintegrating tablet coated with film (2023-11-28),

5. 11786472 - Preparation containing saxagliptin and method for producing the same (2023-10-17),

6. 11406600 - Anhydrous dasatinib-containing preparation (2022-08-09),

7. 11173122 - Additive composition for orally disintegrating tablet (2021-11-16),

8. 11167031 - Additive composition for orally disintegrating tablet (2021-11-09),

9. 10989647 - Orally disintegrating tablet evaluating method, and orally disintegrating tablet evaluating device (2021-04-27),

10. 10925861 - Mirabegron-containing tablet, method for producing mirabegron-containing pharmaceutical preparation, and method for producing mirabegron-containing granulated product (2021-02-23),

11. 10890572 - Mouthfeel evaluation method and mouthfeel evaluation apparatus for orally disintegrating test object (2021-01-12),

12. 10842760 - Sustained-release preparation containing pseudoephedrine or a pharmaceutically acceptable salt thereof (2020-11-24),

13. 10588856 - Orally disintegrating tablet coated with film (2020-03-17),

14. 9561213 - Candesartan cilexetil-containing preparation (2017-02-07),

15. 9399064 - Pitavastatin-containing preparation and method for producing same (2016-07-26),

Established in 1929, SAWAI PHARMACEUTICAL CO., LTD. is a leading pharmaceutical company based in Japan. With a strong focus on research and development, SAWAI PHARMACEUTICAL aims to provide high-quality healthcare solutions to improve the well-being of people worldwide. The company specializes in manufacturing a wide range of innovative pharmaceutical products and actively contributes to the advancement of medical science. SAWAI PHARMACEUTICAL is committed to ensuring the highest standards of quality, safety, and efficacy in its products and strives to create a healthier future for all.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

28 Patents

#228 in Osaka

#2,359 in Japan

#22,542 in the World

Sawai Pharmaceutical Co., Ltd.

Forward Citations = 61

56 inventors:

Yoshiko Kato (10 out of 10 patents)

Junji Yoshinaga (9 out of 9 patents)

Kenji Nozawa (8 out of 9 patents)

4. Hiroaki Kikuoka (7 out of 7 patents)

5. Wataru Izui (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…